Aspergillus osteomyelitis in chronic granulomatous disease: treatment with recombinant gamma-interferon and itraconazole. 1996

S Pasic, and M Abinun, and B Pistignjat, and B Vlajic, and J Rakic, and L Sarjanovic, and N Ostojic
Mother and Child Health Institute, Belgrade, Yugoslavia.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D008297 Male Males
D010019 Osteomyelitis INFLAMMATION of the bone as a result of infection. It may be caused by a variety of infectious agents, especially pyogenic (PUS - producing) BACTERIA. Osteomyelitides
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006105 Granulomatous Disease, Chronic A defect of leukocyte function in which phagocytic cells ingest but fail to digest bacteria, resulting in recurring bacterial infections with granuloma formation. When chronic granulomatous disease is caused by mutations in the CYBB gene, the condition is inherited in an X-linked recessive pattern. When chronic granulomatous disease is caused by CYBA, NCF1, NCF2, or NCF4 gene mutations, the condition is inherited in an autosomal recessive pattern. Autosomal Recessive Chronic Granulomatous Disease,Chronic Granulomatous Disease,Chronic Granulomatous Disease, Atypical,Chronic Granulomatous Disease, X-Linked,Cytochrome B-Negative Granulomatous Disease, Chronic, X-Linked,Cytochrome B-Positive Granulomatous Disease, Chronic, X-Linked,Granulomatous Disease, Chronic, X-Linked,Granulomatous Disease, Chronic, X-Linked, Variant,X-Linked Chronic Granulomatous Disease,Chronic Granulomatous Disease, X Linked,Chronic Granulomatous Diseases,Granulomatous Diseases, Chronic,X Linked Chronic Granulomatous Disease
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000935 Antifungal Agents Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. Anti-Fungal Agents,Antifungal Agent,Fungicides, Therapeutic,Antibiotics, Antifungal,Therapeutic Fungicides,Agent, Antifungal,Anti Fungal Agents,Antifungal Antibiotics
D001228 Aspergillosis Infections with fungi of the genus ASPERGILLUS. Aspergillus Infection,Aspergilloses,Aspergillus Infections,Infection, Aspergillus,Infections, Aspergillus

Related Publications

S Pasic, and M Abinun, and B Pistignjat, and B Vlajic, and J Rakic, and L Sarjanovic, and N Ostojic
May 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
S Pasic, and M Abinun, and B Pistignjat, and B Vlajic, and J Rakic, and L Sarjanovic, and N Ostojic
January 1992, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
S Pasic, and M Abinun, and B Pistignjat, and B Vlajic, and J Rakic, and L Sarjanovic, and N Ostojic
December 1989, The Journal of pediatrics,
S Pasic, and M Abinun, and B Pistignjat, and B Vlajic, and J Rakic, and L Sarjanovic, and N Ostojic
January 1992, Journal of pediatric orthopedics,
S Pasic, and M Abinun, and B Pistignjat, and B Vlajic, and J Rakic, and L Sarjanovic, and N Ostojic
October 1992, Clinical pharmacy,
S Pasic, and M Abinun, and B Pistignjat, and B Vlajic, and J Rakic, and L Sarjanovic, and N Ostojic
April 1991, The Journal of infectious diseases,
S Pasic, and M Abinun, and B Pistignjat, and B Vlajic, and J Rakic, and L Sarjanovic, and N Ostojic
May 2010, Medical mycology,
S Pasic, and M Abinun, and B Pistignjat, and B Vlajic, and J Rakic, and L Sarjanovic, and N Ostojic
February 1991, Current opinion in immunology,
S Pasic, and M Abinun, and B Pistignjat, and B Vlajic, and J Rakic, and L Sarjanovic, and N Ostojic
June 1988, Hematology/oncology clinics of North America,
S Pasic, and M Abinun, and B Pistignjat, and B Vlajic, and J Rakic, and L Sarjanovic, and N Ostojic
February 2000, The British journal of dermatology,
Copied contents to your clipboard!